These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 14991049)

  • 1. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.
    Torres VE; Wang X; Qian Q; Somlo S; Harris PC; Gattone VH
    Nat Med; 2004 Apr; 10(4):363-4. PubMed ID: 14991049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.
    Gattone VH; Wang X; Harris PC; Torres VE
    Nat Med; 2003 Oct; 9(10):1323-6. PubMed ID: 14502283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of vasopressin antagonists.
    Torres VE
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1212-8. PubMed ID: 18434616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug.
    Meijer E; Gansevoort RT; de Jong PE; van der Wal AM; Leonhard WN; de Krey SR; van den Born J; Mulder GM; van Goor H; Struck J; de Heer E; Peters DJ
    Nephrol Dial Transplant; 2011 Aug; 26(8):2445-53. PubMed ID: 21393612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic interventions for autosomal dominant polycystic kidney disease.
    Edelstein CL
    Nephrol News Issues; 2008 Mar; 22(3):25-6. PubMed ID: 18372677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease.
    Chang MY; Parker E; El Nahas M; Haylor JL; Ong AC
    J Am Soc Nephrol; 2007 Feb; 18(2):560-9. PubMed ID: 17202412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel?
    Walz G
    Nephrol Dial Transplant; 2006 Jul; 21(7):1752-7. PubMed ID: 16705023
    [No Abstract]   [Full Text] [Related]  

  • 8. [Polycystic kidney disease].
    Higashihara E
    Nihon Jinzo Gakkai Shi; 2007; Suppl 50th Ann():83-90. PubMed ID: 17899832
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.
    Wang X; Gattone V; Harris PC; Torres VE
    J Am Soc Nephrol; 2005 Apr; 16(4):846-51. PubMed ID: 15728778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.
    Wang X; Harris PC; Somlo S; Batlle D; Torres VE
    Nephrol Dial Transplant; 2009 Feb; 24(2):526-34. PubMed ID: 18826972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Modern treatment of autosomal dominant polycystic kidney disease].
    Wołyniec W; Jankowska MM; Rutkowski B
    Pol Merkur Lekarski; 2008 Oct; 25(148):374-9. PubMed ID: 19145940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy.
    Wüthrich RP; Serra AL; Kistler AD
    Kidney Blood Press Res; 2009; 32(5):380-7. PubMed ID: 19887826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice.
    Ahrabi AK; Terryn S; Valenti G; Caron N; Serradeil-Le Gal C; Raufaste D; Nielsen S; Horie S; Verbavatz JM; Devuyst O
    J Am Soc Nephrol; 2007 Jun; 18(6):1740-53. PubMed ID: 17475819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug therapy for polycystic kidney disease: a review and perspective.
    Aguiari G; Catizone L; Del Senno L
    Am J Nephrol; 2013; 37(2):175-82. PubMed ID: 23428809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autosomal dominant polycystic kidney disease: time for a change?
    Chapman AB
    J Am Soc Nephrol; 2007 May; 18(5):1399-407. PubMed ID: 17429048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular characterization of Pkd2(+/LacZ) mice, an animal model for the autosomal dominant polycystic kidney disease type 2 (ADPKD2).
    Stypmann J; Engelen MA; Orwat S; Bilbilis K; Rothenburger M; Eckardt L; Haverkamp W; Horst J; Dworniczak B; Pennekamp P
    Int J Cardiol; 2007 Aug; 120(2):158-66. PubMed ID: 17182135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model.
    Zafar I; Tao Y; Falk S; McFann K; Schrier RW; Edelstein CL
    Am J Physiol Renal Physiol; 2007 Sep; 293(3):F854-9. PubMed ID: 17581927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.